Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tilray Brands Inc (NQ: TLRY )

1.310 +0.020 (+1.55%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Tilray Brands Inc

< Previous 1 2 3 4 5 6 7 8 9
...
89 90 Next >
German Cannabis: 20 Tons, 10M Grams - And That's Only 0.3% Of The Market, What's Missing?
Medical cannabis users still represent less than 0.3% of the population, indicating significant potential for market expansion. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabis Stocks Feel The Burn: Matt Gaetz Bows Out As Trump's Attorney General Nominee
The AdvisorShares Pure US Cannabis ETF (NYSEARCA: MSOS), often viewed as a benchmark for MSOs, dropped by -4.31%, closing at $4.56. 
Via Benzinga
Topics Cannabis ETFs Government
Exposures Cannabis Political
Prediction: Tilray Brands Won't Be a Cannabis Company in 5 Years
Via The Motley Fool
Topics Cannabis
Exposures Cannabis
These 2 Marijuana Stocks Could Surge Under Trump's Second Term
Via The Motley Fool
Topics Cannabis Government
Exposures Cannabis Political
Beverages, Alcohol and Tobacco Stocks Q3 Recap: Benchmarking Tilray Brands (NASDAQ:TLRY)
Looking back on beverages, alcohol and tobacco stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Tilray Brands (NASDAQ:TLRY) and its peers. 
Via StockStory
Topics Cannabis
Exposures Cannabis
How Is The Market Feeling About Tilray Brands?
Via Benzinga
Is Tilray Brands Stock a Buy?
Tilray is beaten down, but that alone doesn't make it cheap. 
Via The Motley Fool
Q3 Earnings Outperformers: Celsius (NASDAQ:CELH) And The Rest Of The Beverages, Alcohol and Tobacco Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Celsius (NASDAQ:CELH) and the best and worst... 
Via StockStory
Topics Cannabis
Exposures Cannabis
Shareholder Lawsuit Challenges Tilray's Voting Tactics For Authorized Share Increase
Tilray faces a new shareholder lawsuit accusing the company of misleading voting practices, following a $39.9M settlement over similar issues 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Tilray Joins German Cannabis Fiesta With First Locally Grown Strains
Tilray Medical launches its first German-grown cannabis products under a new cultivation license, tapping into Germany's expanding market... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
CBD Pioneer Charlotte's Web Narrows Loss In Q3, Focuses On Long-Term Growth
Charlotte's Web Holdings, Inc. (TSX: CWEB) (OTCQX: CWBHF) a producer of hemp-derived CBD and other botanical wellness products, reported on Thursday financial results for the third quarter ended Sept.... 
Via Benzinga
Does the Rejection of Top Marijuana Legalization Measures Doom the Pot Industry?
The American electorate seems to have turned against weed legal reform. 
Via The Motley Fool
Topics Cannabis
Exposures Cannabis
Cannabis Stocks Pop Following Chris Christie's Prediction That Trump Will Deschedule Cannabis
Cannabis stocks rally on prediction of Trump descheduling marijuana; MSOS leads gains with a 15% surge, followed by Cronos at nearly 13%. 
Via Benzinga
Topics Cannabis Government
Exposures Cannabis Political
Cannabis Stocks: Is It Time To Buy The Dip After Elections And Legalization Setbacks?
After a post-election plunge, cannabis stocks are showing signs of recovery. We analyze Tilray, SNDL, Trulieve, MSOS – time to buy the dip? 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Aurora vs. Canopy & Tilray: Which NASDAQ-Listed Cannabis Stock Offers The Best Growth Potential?
Aurora's international medical cannabis business bolstered its results, with European sales doubling quarter-over-quarter. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabis Extract Significantly Reduces Chemotherapy-Induced Vomiting, Tilray-Backed Study Reveals
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabis Stocks Collapse After Trump Win: Major Players See Double-Digit Declines At Wednesday's Close
Following Trump's presidential election victory, the cannabis sector took a sharp downturn. Here's a summary of what happened today. 
Via Benzinga
Topics Cannabis Government
Exposures Cannabis Political
Tilray, Trulieve And Other Cannabis Stocks Nosediving As Industry Faces New Wave Of Political Uncertainty
Cannabis stocks plunge as Florida's legalization fails and GOP Senate control tempers expectations for industry growth. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Tilray, High Tide, Glass House: How Top Cannabis Companies Deal With Financial Pressures
Discover how cannabis stocks like Tilray, High Tide, and Glass House adapt strategies amid election uncertainty and market volatility. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabis Stocks Sink Amid Broader Market Decline And Election Jitters
Cannabis stocks drop amid broader market downturn and election uncertainty, with major players like Tilray and Aurora Cannabis w/ losses. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
3 Stocks That Have Generated Terrifying Returns for Investors Over the Past 5 Years
Boo! These stocks have all lost more than half of their value in just five years. 
Via The Motley Fool
Beyond Beer, Tilray's $1.67 Billion Market Play: Is This Cannabis Giant Still A Smart Buy?
Zuanic & Associates rates Tilray "Neutral," noting long-term potential but near-term uncertainties, despite cannabis growth in Germany. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Canada's Cannabis Market Goes Cold, Pot Prices Hit Bottom: Why Top Producers Are Losing Ground
Amid this slowdown, certain products capture consumer interest, even as prices stabilize and competition intensifies. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
EXCLUSIVE: Tilray CEO Irwin Simon On Why US Cannabis Rescheduling Won't Change A Billion-Dollar Play
CEO Irwin Simon addressed the recent quarterly performance and challenges the company faces in both domestic and international markets. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Keurig Dr Pepper (KDP) To Report Earnings Tomorrow: Here Is What To Expect
Beverage company Keurig Dr Pepper (NASDAQ:KDP) will be reporting results tomorrow morning. Here’s what to look for. 
Via StockStory
Female Cannabis Consumers Outspend Men: How Tilray And High Tide Are Responding
Young women now lead cannabis consumption in the U.S., prompting retailers to adapt their products and strategies to meet this demand. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Marijuana Stock Movers For October 22, 2024
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabis Stock Movers For October 22, 2024
Via Benzinga
Topics Cannabis
Exposures Cannabis
Billion-Dollar Cannabis And Beverage Giant Brings Oktoberfest Vibes To Your Glass With New Craft Beers
Tilray announced a series of fall-themed product launches across its craft beer and beverage brands. Those include Breckenridge Brewery, Montauk Brewing, Blue Point Brewing, Terrapin and Shock... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Tilray CEO Irwin Simon: 2024 Election Likely To Drive U.S. Cannabis Legalization, No Matter Who Wins
Tilray CEO Irwin Simon says the 2024 election is key for cannabis reform, with both presidential candidates backing legalization. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
< Previous 1 2 3 4 5 6 7 8 9
...
89 90 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.